Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07900516). This is a study registration, not published results. Lead sponsor: The First Affiliated Hospital with Nanjing Medical University. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DRUG: Kumoxili; DRUG: Docetaxel; DRUG: Epirubicin; DRUG: Cyclophosphamide; DRUG: Letrozole; DRUG: Everolimus (Afinitor®). Primary outcome measures: ORR , up to 18 weeks. Brief summary: To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy.